Thermo Fisher raises profit forecast on strong demand for its tools and services
Oct 23 (Reuters) -Thermo Fisher Scientific TMO.N on Wednesday raised the lower end of its annual profit forecast, tweaking it for the third time this year, betting on improved demand for its tools and services used in drug development.
Contract drug manufacturers witnessed reduced spending from biotech clients last year, but recent interest cuts could improve the funding environment for biotechs as borrowing costs might ease.
Thermo, which had raised its profit forecast range twice earlier this year, now expects annual profit between $21.35 and $22.07 per share, compared with previous forecast of $21.29 to $22.07 per share.
On Tuesday, rival Danaher DHR.N beat Wall Street estimates for profit and revenue, but said that it is not seeing large improvement in demand from smaller biotechs and flagged weakness in China.
Thermo Fisher retained its annual revenue forecast in the range of $42.4 billion to $43.3 billion.
Analysts are expecting a profit of $21.72 per share and revenue of $42.91 billion for this year, according to LSEG data.
For the third quarter, sales in the company's laboratory products segment that provides products and services used in clinical trials and drug development came in at $5.74 billion, above analysts' expectations of $5.45 billion.
Revenue from that segment makes up more than half of Thermo Fisher's total sales.
European peer Sartorius SATG.DE last week reported better-than-expected bioprocessing order intake in its nine-month results, lifting shares of life sciences firms like Thermo Fisher, Danaher and Waters WAT.N. Citi analysts had said the results were "a clear positive data point for bioprocessing players".
On an adjusted basis, Waltham, Massachussets-based Thermo earned $5.28 per share for the quarter ended Sept. 28, compared with analysts' expectations of $5.25 per share.
However, its third-quarter revenue of $10.60 billion fell short of estimates of $10.64 billion.
Reporting by Christy Santhosh in Bengaluru; Editing by Shailesh Kuber
免责声明: XM Group仅提供在线交易平台的执行服务和访问权限，并允许个人查看和/或使用网站或网站所提供的内容，但无意进行任何更改或扩展，也不会更改或扩展其服务和访问权限。所有访问和使用权限，将受下列条款与条例约束：(i) 条款与条例；(ii) 风险提示；以及(iii) 完整免责声明。请注意，网站所提供的所有讯息，仅限一般资讯用途。此外，XM所有在线交易平台的内容并不构成，也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。
所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。
本网站上由XM和第三方供应商所提供的所有内容，包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接，皆保持不变，并作为一般市场评论所提供，而非投资性建议。所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为适用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解，XM非独立投资研究提示和风险提示相关资讯，更多详情请点击 这里。
